How does the MMAF component of the ADC function to kill cancer cells?

MMAF, the drug portion of the ADC, binds to tubulins, which are integral parts of the cell's cytoskeleton. By binding to these tubulins, MMAF disrupts microtubule dynamics, leading to cell cycle arrest and eventually inducing apoptosis or cell death.

For what purpose is the anti-RIgG(HL)-C-MMAF ADC primarily used in research?

The primary use of the anti-RIgG(HL)-C-MMAF ADC in research is to pre-screen rabbit monoclonal antibodies as ADC candidates. This secondary antibody linked to MMAF offers a cost-effective and efficient approach to determining the potential efficacy of new monoclonal antibodies in ADC therapies.

Can the anti-RIgG(HL)-C-MMAF ADC be used alone in therapeutic applications?

No, the anti-RIgG(HL)-C-MMAF ADC is not typically used alone in therapeutic applications. It requires a primary antibody to be effective, as it is designed to bind to rabbit IgG antibodies and is used primarily for screening potential ADC candidates rather than direct therapeutic use.

What is the mechanism of action for the anti-RIgG(HL)-C-MMAF ADC?

The anti-RIgG(HL)-C-MMAF ADC functions by utilizing an anti-rabbit IgG(H+L) specific polyclonal antibody conjugated to the cytotoxic agent MMAF. MMAF binds to tubulins, disrupting microtubule dynamics and ultimately leading to cell death. This mechanism is particularly useful in pre-screening rabbit monoclonal antibodies as ADC candidates.

What are the key advantages of using anti-RIgG(HL)-C-MMAF ADC over traditional pre-screening methods?

The anti-RIgG(HL)-C-MMAF ADC offers a more efficient and economical alternative for pre-screening rabbit monoclonal antibodies as ADC candidates. Its design minimizes unnecessary toxicity without a primary antibody, allowing for a focused evaluation of potential ADCs.

What factors should be considered when using the anti-RIgG(HL)-C-MMAF ADC in research?

When using the anti-RIgG(HL)-C-MMAF ADC, it is important to consider the specificity of the primary antibody, the linker stability, and the experimental conditions to ensure optimal targeting and cytotoxicity. Additionally, appropriate controls should be included to validate the results.

Home
Products
Anti-Ab ADCs
IgG (H+L)
anti-RIgG(HL)-C-MMAF ADC

anti-RIgG(HL)-C-MMAF ADC (CAT#: ADC-AA-035)

This ADC product is comprised of an anti-rabbit IgG(H+L) specific polyclonal antibody conjugated via a cleavable linker to MMAF. The antibody portion is a secondary antibody and the drug portion, MMAF, is a cytotoxic small molecule which binds to tubulins, interrupts microtubule dynamics, and induces cell death. This product displays no obvious toxicity without a primary antibody and can be a quite efficient and economical alternative to pre-screening rabbit monoclonal antibodies as ADC candidates.

ADC Target
ADC Antibody
ADC Linker
ADC payload drug

Name
IgG(H+L)

Overview
IgG antibody subtype is the most abundant serum immunoglobulins of the immune system, which is a protein complex composed of four peptide chains—two identical heavy chains and two identical light chains arranged in a Y-shape typical of antibody monomers. IgG is secreted by B cells and is found in blood and extracellular fluids and provides protection from infections caused by bacteria, fungi and viruses.

Overview
anti-rabbit IgG(H+L) specific polyclonal IgG antibody

Species Reactivity
Rabbit

Name
Cleavable linkers

Description
Cleavable linkers rely on the physiological stimuli, which mainly include chemically cleavable linkers and enzymatically cleavable linkers. Chemically cleavable linkers including acid-labile linkers and disulfide linkers. For acid-labile linkers, intracellular release of payloads relies on the different pH between endosomes/lysosomes and blood. The release of disulﬁde-linked drugs is controlled by the factors in intracellular environment. Enzymatically cleavable linkers, peptide linkers and β-glucuronide linkers, are sensitive to enzymes located in cytoplasm.

Name
MMAF (Monomethyl auristatin F)

Description
Derived from Auristatin,are water-soluble dolastatin analogs of dolastatin 10. Dolastatin 10 belongs to dolastatin family and it can powerfully bind to tubulin, thus inhibiting polymerization mediated through the binding to the vinca alkaloid binding domain, and causes cell to accumulate in metaphase arrest.

For Research Use Only. NOT FOR CLINICAL USE.

Published Data

+ Submit Publications

Submit a review or a question

Scientific Resources

CAMouse™-Fully Human Antibody Generation Platform

Reviews

Literature

Protocol

Customer Reviews and FAQs

There are currently no Customer reviews or questions for ADC-AA-035. Click the button above to contact us or submit your feedback about this product.

Customer Reviews FAQ

Excellent

Using the anti-RIgG(HL)-C-MMAF ADC significantly enhanced our pre-screening process for rabbit monoclonal antibodies. It's efficient and offers a robust alternative with minimal toxicity concerns.

Excellent

This ADC product combines efficacy with safety, making it an indispensable tool in our lab. It effectively targets tubulins and induces cell death without adverse effects.

Excellent

We observed remarkable results in our experiments with the anti-RIgG(HL)-C-MMAF ADC. It's a game changer for targeting and eradicating disease-causing agents in our models.

Excellent

The specificity of the anti-RIgG(HL)-C-MMAF ADC is outstanding. It binds perfectly without a primary antibody, providing a clear path for antibody evaluation.

Excellent

I was impressed with how the anti-RIgG(HL)-C-MMAF ADC operated under our experimental conditions. It provided consistent results without any observable toxicity.

Excellent

The performance of anti-RIgG(HL)-C-MMAF ADC in our recent studies was beyond expectations. It's reliable, effective, and crucial for our ongoing research in antibody therapeutics.

Q: 1: How does the MMAF component of the ADC function to kill cancer cells?
A: MMAF, the drug portion of the ADC, binds to tubulins, which are integral parts of the cell's cytoskeleton. By binding to these tubulins, MMAF disrupts microtubule dynamics, leading to cell cycle arrest and eventually inducing apoptosis or cell death.
Q: 2: For what purpose is the anti-RIgG(HL)-C-MMAF ADC primarily used in research?
A: The primary use of the anti-RIgG(HL)-C-MMAF ADC in research is to pre-screen rabbit monoclonal antibodies as ADC candidates. This secondary antibody linked to MMAF offers a cost-effective and efficient approach to determining the potential efficacy of new monoclonal antibodies in ADC therapies.
Q: 3: Can the anti-RIgG(HL)-C-MMAF ADC be used alone in therapeutic applications?
A: No, the anti-RIgG(HL)-C-MMAF ADC is not typically used alone in therapeutic applications. It requires a primary antibody to be effective, as it is designed to bind to rabbit IgG antibodies and is used primarily for screening potential ADC candidates rather than direct therapeutic use.
Q: 4: What is the mechanism of action for the anti-RIgG(HL)-C-MMAF ADC?
A: The anti-RIgG(HL)-C-MMAF ADC functions by utilizing an anti-rabbit IgG(H+L) specific polyclonal antibody conjugated to the cytotoxic agent MMAF. MMAF binds to tubulins, disrupting microtubule dynamics and ultimately leading to cell death. This mechanism is particularly useful in pre-screening rabbit monoclonal antibodies as ADC candidates.
Q: 5: What are the key advantages of using anti-RIgG(HL)-C-MMAF ADC over traditional pre-screening methods?
A: The anti-RIgG(HL)-C-MMAF ADC offers a more efficient and economical alternative for pre-screening rabbit monoclonal antibodies as ADC candidates. Its design minimizes unnecessary toxicity without a primary antibody, allowing for a focused evaluation of potential ADCs.
Q: 6: What factors should be considered when using the anti-RIgG(HL)-C-MMAF ADC in research?
A: When using the anti-RIgG(HL)-C-MMAF ADC, it is important to consider the specificity of the primary antibody, the linker stability, and the experimental conditions to ensure optimal targeting and cytotoxicity. Additionally, appropriate controls should be included to validate the results.

Quick Links

ADC Toxins

Drug-linker Complexes

Customized ADCs

Anti-Ab ADCs

Other Products

Same Target Same Linker Same Payload

CAT#	Product Name	Linker	Payload
ADC-AA-045	anti-Rat IgG(HL)-N-MMAF ADC	Noncleavable linkers	MMAF (Monomethyl auristatin F)
ADC-AA-034	anti-RIgG(HL)-N-MMAF ADC	Noncleavable linkers	MMAF (Monomethyl auristatin F)
ADC-AA-036	anti-RIgG(HL)-C-MMAE ADC	Cleavable linkers	MMAE (Monomethyl auristatin E)
ADC-AA-038	anti-RIgG(HL)Fab-C-MMAF ADC	Cleavable linkers	MMAF (Monomethyl auristatin F)
ADC-AA-066	Anti-Rat IgG(H+L)-C-PBD ADC	Cleavable linkers	PBD (pyrrolobenzodiazepine)

CAT#	Product Name	Linker	Payload
ADC-AA-066	Anti-Rat IgG(H+L)-C-PBD ADC	Cleavable linkers	PBD (pyrrolobenzodiazepine)
ADC-AA-011	anti-HIgG(Fc)Fab-C-MMAE ADC	Cleavable linkers	MMAE (Monomethyl auristatin E)
ADC-AA-002	anti-HIgG(Fc)-C-MMAF ADC	Cleavable linkers	MMAF (Monomethyl auristatin F)
WJY-0423-LS107	Protein A-PBD ADC	Cleavable linkers	PBD (pyrrolobenzodiazepine)
ADC-AA-062	Anti-HIgG(Fc)Fab-C-DX8951 ADC	Cleavable linkers	DX8953

CAT#	Product Name	Linker	Payload
ADC-AA-001	anti-HIgG(Fc)-N-MMAF ADC	Noncleavable linkers	MMAF (Monomethyl auristatin F)
ADC-W-493	Anti-CD19-Mc-MMAF ADC-3	Mc (maleimidocaproyl)	MMAF (Monomethyl auristatin F)
ADC-AA-020	anti-MIgG(Fc)-C-MMAF ADC	Cleavable linkers	MMAF (Monomethyl auristatin F)
ADC-W-537	Anti-TPBG-Mc-MMAF ADC	Mc (maleimidocaproyl)	MMAF (Monomethyl auristatin F)
ADC-AA-002	anti-HIgG(Fc)-C-MMAF ADC	Cleavable linkers	MMAF (Monomethyl auristatin F)

Online Inquiry

Welcome! For price inquiries, please feel free to contact us through the form on the left side. We will get back to you as soon as possible.